{"id":"NCT03002571","sponsor":"Bausch Health Americas, Inc.","briefTitle":"Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)","officialTitle":"A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Study to Evaluate the Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-24","primaryCompletion":"2020-04-14","completion":"2020-04-14","firstPosted":"2016-12-23","resultsPosted":"2023-05-08","lastUpdate":"2023-05-08"},"enrollment":338,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"IDP-124 Lotion","otherNames":[]},{"type":"DRUG","name":"IDP-124 Vehicle Lotion","otherNames":[]}],"arms":[{"label":"IDP-124 Lotion","type":"EXPERIMENTAL"},{"label":"IDP-124 Vehicle Lotion","type":"ACTIVE_COMPARATOR"}],"summary":"Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects","primaryOutcome":{"measure":"Percentage of Participants Who Had at Least a 2-grade Reduction From Baseline at Week 6 in the Investigator Global Assessment (IGA) Scale and Had an IGA at Week 6 That Equated to \"Clear\" or \"Almost Clear\"","timeFrame":"Baseline to Week 6","effectByArm":[{"arm":"IDP-124 Lotion","deltaMin":42.95,"sd":null},{"arm":"IDP-124 Vehicle Lotion","deltaMin":27.96,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":224},"commonTop":["Application site dermatitis"]}}